Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice

Circulation

Volumn 96, Issue 12, 1997, Pages 4349-4356

  De Geest, Bart ^b   Zhao, Zhian ^b   Collen, Désiré ^a   Holvoet, Paul ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b NONE

Author keywords

Apolipoproteins; Atherosclerosis; Endothelial injury; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CHOLESTEROL; COMPLEMENTARY DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; ENDOTHELIUM INJURY; GENE TRANSFER; HYPERLIPOPROTEINEMIA TYPE 3; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS PLAQUE; VIRUS RECOMBINANT;

EID: 0031471857     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.12.4349     Document Type: Article

References (45)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707-714.
2. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
3. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;60:455-461.
4. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature. 1991;353:265-267.
5. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994;91:899-903.
6. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1994;91:9607-9611.
7. Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 1993;261:469-472.
8. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 1993;365:762-764.
9. Barter PJ, Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis. 1996;121:1-12.
10. Tall AR. Plasma high density lipoproteins: metabolism and relationship to atherogenesis. J Clin Invest. 1990;86:379-384.
11. Reis GJ, Kuntz RE, Silverman DI, Pasternak RC. Effects of serum lipid levels on restenosis after coronary angioplasty. Am J Cardiol. 1991;68:1431-1435.
12. Shah PK, Amin J. Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation. 1992;85:1279-1285.
13. Ameli S, Hultgardh-Nilsson A, Cercek B, Shah PK, Forrester JS, Ageland H, Nilsson J. Recombinant apolipoprotein A-I Milano reduces intimai thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 1994;90:1935-1941.
14. Mackness MI, Abbott C, Arrol S, Durrington PN. The role of high-density lipoprotein and lipid-sotuble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J. 1993;294: 829-834.
15. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1990;1044:275-283.
16. Mutsudu Y, Hirata K, Inone N, Suematsu M, Kawashima S, Akita H, Yokoyama M. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependem arterial relaxation. Circ Res. 1993;72:1103-1109.
17. Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353.
18. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia und arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468-471.
19. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. Apo E-deticient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133-140.
20. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E: evaluation of lesional development and progression. Arterioscler Thromb. 1994;14:141-147.
21. Holvoet P, Zhao Z, Vanloo B, Vos R, Deridder E, Dhoest A, Taveirne J, Brouwers E, Demarsin E, Engelhorghs Y, Rosseneu M, Collen D, Brasseur R. Phospholipid binding and lecithin-cholesterol acyltransferase activation properties of apolipoprotein A-I mutants. Biochemistry. 1995;34:13334-13342.
22. Goméz-Foix AM, Coats WS, Baqué S, Alam T, Gerard RD, Newgard CB. Adenovirus-mediatcd transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. J Biol Chem. 1992;267:25129-25134.
23. Mc Grory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology. 1988;163:614-617.
24. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36:59-74.
25. Alcorn JL, Gao E, Chen Q, Smith ME, Gerard RD, Mendelson CR. Genomic elements involved in transcriptional regulation of the rabbit surfactant protein A gene. Mol Endocrinol. 1993;7: 1072-1085.
26. Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost. 1985;54:684-7.
27. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A. 1992;89:4471-4475.
28. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res. 1993;73:792-796.
29. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
30. Vercaemst R, Union A, Rosseneu M, De Craene I, De Backer G, Kornitzer M. Quantitation of plasma free cholesterol and cholesterylesters by high performance liquid chromatography: study of a normal population. Atherosclerosis. 1989;78:245-250.
31. Armitage P, Berry G. Statistical Methods in Medical Research. 2nd ed. Oxford, UK: Blackwell Scientific Publications; 1987:110.
32. Declerck PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost. 1995;74:1305-1309.
33. Kopfler WP, Willard M, Betz T, Willard JE, Gerard RD, Meidell RS. Adenovirus-mediuted transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol. Circulaiion. 1994;90:1319-1327.
34. Kitagawa S, Yamaguchi Y, Imaizumi N, Kunitomo M, Fujiwara M. A uniform alteration in serum lipid metabolism occurring during inflammation in mice. Jpn J Pharmacol. 1992;58:37-46.
35. Cabana VG, Gewurz H, Siegel JN. Inflammation induced changes in rabbit CRP and plasma lipoproteins. J Immunol. 1983;130: 1736-1742.
36. Duverger N, Kruth H, Emmanuel F, Caillaud JM, Viglietta C, Castro G, Tailleux A. Fievet C, Fruchart JC, Houdebine LM, Denefle P, Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I transgenic rabbits. Circulation. 1996;94:713-717.
37. Shimano H, Ohsuga J, Shimada M, Namba Y, Gotada T, Harada K, Katsuki M, Yazaki Y, Yamada N. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest. 1995;95:469-476.
38. Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM, Pitas RE. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest. 1995;96:2170-2179.
39. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-630.
40. Huang Y, von Eckardstein A, Wu S, Maeda N, Assmann G. A plasma lipoprotein containing only apolipoprotein E with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci U S A. 1994;91:1834-1838.
41. Kume N, Gimbrone MA Jr. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest. 1994;93:907-911.
42. Bjorkerud S, Bjorkerud B. Lipoproteins are major and primary mitogens and growth promoters for human arterial smooth muscle cells and lung fibroblasts in vitro. Arterioscler Thromb. 1994;14: 288-298.
43. Ko Y, Haring R, Stiebler H, Wieczorek AJ, Vetter H, Sachinidis A. High-density lipoprotein reduces epidermal growth factor-induced DNA synthesis in vascular smooth muscle cells. Atherosclerosis. 1993;99:253-259.
44. Liu M, Subbaiah PV. Activation of plasma lysolecithin acyltransferase reaction by apolipoproteins A-I, C-I and E. Biochim Biophys Acta. 1993;1168:144-152.
45. Sullivan TR Jr, Karas RH, Aronovitz M, Faller GT, Ziar JP, Smith JJ, O'Donnell TF Jr, Mendelsohn ME. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest. 1995;96:2482-2488.